Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MRG-110 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose - MRG-110 | EXPERIMENTAL | Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites |
| Single Ascending Dose - Placebo | PLACEBO_COMPARATOR | Intradermal injection of placebo at four wound sites |
| Multiple Ascending Dose - MRG-110 | EXPERIMENTAL | Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites |
| Multiple Ascending Dose - Placebo | PLACEBO_COMPARATOR | Intradermal injection of placebo at four wound sites |
| Name | Type | Description |
|---|---|---|
| MRG-110 | DRUG | Single ascending doses of MRG-110 |
| Placebo | DRUG | Single doses of placebo |
Key Inclusion Criteria: * Normal healthy volunteers. * Females must be of non-childbearing potential. * If engaged in sexual relations with a female of child-bearing potential, males must be surgically sterile or must be willing to use a highly effective method of contraception throughout their stu...
MRG-110 is an investigational small molecule being studied for use in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics following intradermal injection.
MRG-110 is being developed by CASI Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol CASI. The company is conducting clinical research on this investigational small molecule in the United States.
MRG-110 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, involving 42 healthy volunteers in the United States.
MRG-110 has one completed clinical trial, identified as NCT03603431. This Phase 1 study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of MRG-110 following intradermal injection in healthy volunteers. The trial was randomized, double-blind, and placebo-controlled.
No alternative names for MRG-110 have been reported. It is identified solely by the code name MRG-110 in clinical trial records and is being developed as a distinct investigational small molecule by CASI Pharmaceuticals.